Stock Ratings / Health Care / HYPR / forecast

OM (34) ECOR (29) STXS (22) NRXS (36) ⌘ Pro Terminal →

Hyperfine Inc. (Class A) (HYPR) 12-Month Stock Forecast & Price Target Cone

$0.72 -3.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.71

Hyperfine Inc. (Class A) (HYPR) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $76.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HYPR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HYPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Hyperfine Inc. (Class A) (NASDAQ: HYPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.72 (-3.50% 1D, market cap $76.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HYPR ranks #512 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HYPR compare to OM and ECOR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), HYPR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 49.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M) and ECOR (electroCore Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M). Among the 5-stock peer group, HYPR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HYPR?

▼

Per HYPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833769), Hyperfine Inc. (Class A) generated $13.6M in revenue (+5.2% YoY), -$35.6M in net income, and -$29.1M in free cash flow against $55.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.71 (-0.82%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HYPR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY HYPR SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 49.8% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.85-9.4% Next Q

Q2 (-2Q)

Grade D$0.77-2.6% Next Q

Q3 (-1Q)

Grade D$0.75-4% Next Q

Current

Grade D-$0.72-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HYPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HYPR currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.81) and Max Pain ($0.76) forces dealer call-delta covering toward $2.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HYPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HYPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your HYPR Position Size: $10,000

Shares at $0.72: 13888.9 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.51

$7,083

$-2,917 (-29.2%)

12M Consensus BaseTarget $0.66

$9,167

$-833 (-8.3%)

12M Bull Case BreakoutTarget $2.03

$28,194

+$18,194 (+181.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$2	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HYPR)

✓Walkthrough of HYPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HYPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -60.22%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.75H $0.75L $0.72C $0.72VOL 565.6K

RES: $1.05SUP: $0.64SMA50: $0.81SMA200: $1.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HYPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HYPR Butterfly Map → + Track HYPR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HYPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HYPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HYPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HYPR)

Health Care Rank #512 of 1016 ⚔️ OM vs HYPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HYPR vs. OM, ECOR, STXS, NRXS)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Hyperfine Inc. (Class A) (HYPR) ranks #512 by composite RQD confidence (38/100, grade D-) and #687 by equity capitalization ($76.1M). Within this direct 5-issuer industry benchmark cohort, HYPR leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HYPR ACTIVE Hyperfine Inc. (Class A)	D-	38/100	—	49.8%	-35.0%	-3.50%	$76.1M	Benchmark Subject
OM Outset Medical Inc.	E	34/100	—	39.1%	-28.0%	-3.82%	$75.8M	/om-vs-hypr →
ECOR electroCore Inc.	E	29/100	—	86.8%	-35.0%	-7.27%	$67.8M	/ecor-vs-hypr →
STXS Stereotaxis Inc.	E	22/100	—	52.7%	-35.0%	-5.21%	$86.4M	/stxs-vs-hypr →
NRXS Neuraxis Inc.	D-	36/100	—	84.2%	-35.0%	-5.56%	$89.5M	/nrxs-vs-hypr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001833769

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hyperfine Inc. (Class A) (HYPR) reported GAAP revenue of $13.6M (+5.2% vs. FY2024 revenue of $12.9M , and +22.9% cumulative change since FY2023) , GAAP net income of -$35.6M, operating cash flow of -$27.9M, and free cash flow of -$29.1M (+25.6% YoY). On the balance sheet, HYPR closed FY2025 with $55.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$13.6M	-$35.6M	-$27.9M	-$29.1M	$55.3M	$0
FY2024 (FY)	2024-12-31	$12.9M	-$40.7M	-$38.8M	-$39.1M	$58.9M	—
FY2023 (FY)	2023-12-31	$11.0M	-$44.2M	-$41.8M	-$41.8M	—	—

3. HYPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HYPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HYPR compare to OM and ECOR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HYPR?

Where is HYPR trading relative to its 50-day, 200-day, and 52-week technical levels?

HYPR last traded at $0.72 (-3.50% on volume of 565,605 shares), positioning the stock -11.11% below its 50-day simple moving average ($0.81) and -36.28% below its 200-day simple moving average ($1.13). Across its 52-week range of $0.70 to $1.93, HYPR sits at the 1.6% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).

HYPR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is HYPR's 12-month stock price target?

Hyperfine Inc. (Class A) (HYPR) carries a 12-month consensus base price target of $0.66 (-8.3% from $0.72), with a bull-case target of $2.03 and a bear-case floor of $0.51.

Is HYPR stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates HYPR D- (Sell — SELL) with an RQD Confidence score of 38/100.

Direct Sub-Reports: HYPR RQD Cockpit HYPR 12M Forecast HYPR Earnings & Move HYPR Dividends & DRIP HYPR Insiders & 13F HYPR Whale Options HYPR Profit Sankey HYPR News & Why

Sector Peer Dials

Precision Optics Corporation Inc.

31 /100

HYPR Core Snapshot

Market Cap $76.1M

Trailing / Fwd P/E — / —

Gross Profit Margin 49.8%

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield —

12M Base Price Target $0.66

FREE TRADER TOOLS

Own HYPR Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With HYPR → 🏆 Trade HYPR in $100K Prop Arena →

HYPR Wire

Why It Moved →

Peer / Ecosystem Wire Yahoo Finance • 17h ago

Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% Sequentially

Direct Company Event StockInvest.us • 20h ago

Hyperfine Stock Price Forecast. Should You Buy HYPR?

Direct Company Event TradingView • 23h ago

Hyperfine, Inc. Estimates – NASDAQ:HYPR

Peer / Ecosystem Wire Benzinga • 1d ago

Full Transcript: Hyperfine Q2 2026 Earnings Call

Direct Company Event Quiver Quantitative • 1d ago

Hyperfine Reports Preliminary Q3 Revenue of Approximately $6.0 Million | HYPR Stock News

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HYPR — Hyperfine Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:45:06Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HYPR scores 38 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 6/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Whale/13F Flow, while the Forensic Balance Sheet is the strongest relative to its weight. For a prospective investor, the rating points to an operating model that is not currently self-funding: the cash-engine pillar and the 0% FCF yield indicate that the upside case depends on improvement in operating economics rather than on present cash generation. The balance-sheet pillar offers some comfort on solvency metrics, but the rating's overall verdict reflects weak flow signals and limited insider conviction. Any valuation tradeoff is therefore driven by whether revenue growth can narrow the operating loss, which the source data does not establish.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$13.6M	$-37.1M	$-35.6M	N/A	$-29.1M	$35.1M	$0.0M
FY 2024	$12.9M	$-43.2M	$-40.7M	N/A	$-39.1M	$37.6M	N/A
FY 2023	$11.0M	$-48.1M	$-44.2M	N/A	$-41.8M	N/A	N/A

Per the SEC financials, revenue rose from $11.0M in FY 2023 to $13.6M in FY 2025, while net income remained negative across all three periods. Per the market data, the gross margin is 49.8%, with operating and net margins of -60% and ROIC of -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with a Debt/Equity ratio of 0.5. Per the SEC financials, FY 2025 cash was $35.1M against reported debt of $0.0M.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the top-ranked item is a Yahoo Finance report headlined "Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% Sequentially," flagged as a GREEN catalyst. Other items from StockInvest.us, TradingView, Benzinga, Quiver Quantitative, and Stock Titan are flagged YELLOW as market-wire coverage, including a Q2 2026 earnings call transcript. The Stock Titan item concerns an unrelated German symphony performance involving brain scans and carries limited fundamental relevance. Per the Butterfly Supply-Chain Graph, there is no supply-chain classification ("NONE"), no butterfly links, and no proprietary signals. Risk watch items include the sustained operating loss shown in the SEC financials and the -5.23% price change in the market data.

Open Questions

What are the company's specific products, customers, and revenue drivers behind the FY 2025 revenue of $13.6M?
What is the company's cash runway given FY 2025 FCF of $-29.1M against cash of $35.1M, and what is the FY 2024 cash balance comparison?
What is the status of the "record preliminary Q3 revenue" catalyst, and how does it reconcile with the reported losses?
Why are analyst data, holder data, and forward-looking estimates unavailable in the source data?
What is the debt structure behind the reported Debt/Equity ratio of 0.5 given FY 2025 debt of $0.0M?

HYPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Hyperfine Inc. (Class A) (HYPR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HYPR Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 17h ago

Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% Sequentially

Yahoo Finance report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 20h ago

Hyperfine Stock Price Forecast. Should You Buy HYPR?

StockInvest.us report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

Hyperfine, Inc. Estimates – NASDAQ:HYPR

TradingView report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Full Transcript: Hyperfine Q2 2026 Earnings Call

Benzinga report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

Hyperfine Reports Preliminary Q3 Revenue of Approximately $6.0 Million | HYPR Stock News

Quiver Quantitative report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Six German symphony performances bring brain scans onstage

Stock Titan report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Hyperfine (HYPR) Holds Near $0.72 as Traders Eye $0.68 Support - Inverse ETF Flow

https://www.siam.in/ report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HYPR Bull vs. Bear Conversation Board — What's Your Call at $0.72?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HYPR 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.65 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HYPR (D- • RQD 38/100) a Buy at $0.74?

Welcome to the HYPR (Hyperfine Inc. (Class A)) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Electromedical & Electrotherapeutic Apparatus. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.61 (-17.6%)

Spot @ $0.74

Pump the brakes on HYPR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HYPR, but look at what you are paying: current EV/EBITDA multiples with 49.8% gross margins. Unless Hyperfine Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.85 (+14.9%)

Spot @ $0.74

HYPR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HYPR, the market is fixating on short-term headline noise in Biotechnology: Electromedical & Electrotherapeutic Apparatus and ignoring the balance sheet and cash flow trajectory. At $0.74 (52-wk range $0.70 - $1.93), any beat on forward guidance forces shorts and underweight funds to chase.